KCT0002017已完成未知
A randomized, open-label, three-way crossover clinical trial to compare safety and pharmacokinetic characteristics after single administration of Carol-F Tab, Advil Liqui-Gels and Brufen Tab 200 mg in healthy male volunteers
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 50(Year)（—）
- 性别
- Male
入选标准
- •(1) Healthy man aged between 19(inclusive) and 50(inclusive) at the time of the screening
- •(2) A subject with a body weight over 50 kg (inclusive) and with body mass index (BMI) between 18.5 (inclusive) and 27 (inclusive)
- •(3) A subject who has no congenital disease, no chronic disease requiring treatment, np symptoms of illness and no medical opinions after a medical examination
- •(4) Suitable subject who has considered eligible for the clinical trial based on the results from the clinical laboratory tests including hematology, blood chemistry, serology and urinalysis which were set up and conducted according to the characteristics of the investigational products during the screening
- •(5) A subject who is willing to make himself available for the study period and follow the study protocol, and is able to provide written informed consent after fully understanding the study procedures.
排除标准
- •(1) A subject who has any clinically significant liver disease, kidney disease, nervous system disease, respiratory system disease, endocrine system disease, hemato-oncology disease, urinary system disease, cardiovascular system disease, musculoskeletal system disease or mental disorder, or any medical histories as follows
- •1) Peptic ulcer
- •2) Severe blood disease
- •3) Asthmatic bronchitis
- •4) Treatment of pain occurring after coronary artery bypass graft (CABG)
- •5) Myocardial infarction
- •6) Heart failure
- •(2) A subject with any history of gastrointestinal disease (e.g., Crohn’s disease, acute or chronic pancreatitis, and others) and surgery (except for simple appendectomy or repair of a hernia), which can influence the absorption of investigational products.
- •(3) A subject with hypersensitivity of drugs including Ibuprofen and other drugs (e.g., aspirin, antibiotics, and others) or any history of clinically significant hypersensitivity (e.g., photoallergy, phototoxicity, and others).
- •(4) A subject who has the following clinical laboratory test results
- •? Liver Function Test (AST, ALT) > three times the upper limit of the normal range
- •? eGFR < 60 ml/min/1.73 m2 calculated by MDRD (Modification of Diet in Renal Disease)
- •(5) A subject who has the following vital signs results in sitting position at the time of the screening :
- •SBP = 90 mmHg or DBP = 60 mmHg; SBP = 150 mmHg or DBP = 100 mmHg
- •(6) A subject with a history of drug abuse or a positive urine drug screening for drug abuse
- •(7) A subject who has taken any ethical-the-counter drug, herbal compound (including cyclosporine, aspirin, and others) or has taken any methotrexate, anticoagulant drug (e.g., warfarin), antihypertensive drug, diuretics and others which can be pharmacologically affected by investigational products within 2 weeks prior to the administration of investigational products, or has taken any over-the-counter drug or vitamin supplement within 1 week before the investigational product administration (If, however, the drugs are determined not to be effective in pharmacokinetic characteristics, the subjects can participate in the study according to the judgment of the investigator.).
- •(8) A subject who has participated in any other clinical trials and had medication within 3 months prior to the first administration of investigational product. (The end date of another clinical trial is based on the last day of the administration)
- •(9) A subject who has donated whole blood within 2 months or blood components within 1 month or received a blood transfusion within 1 month prior to the investigational product administration.
- •(10) A subject who consistently drinks alcohol (over 21 units/week, 1 unit = 10 g of pure alcohol) or does not abstain from drinking throughout the clinical trial.
- •(11) A smoker who consumes more than 10 cigarettes on average a day for recent 3 months and who is unable to stop smoking from 48 hours before the administration of investigational products to the last point for blood sampling.
- •(12) A subject who eats or drinks products containing grapefruit and who is unable to stop eating or drinking throughout the study period, from 48 hours before the first administration to the post-study visit.
- •(13) A subject who takes or who is unable to stop eating or drinking products containing caffeine (coffee, green tea, black tea, soda, coffee flavored milk, nutritious tonic, and others) from 48 hours prior to the administration of each study period to the last point f
研究者
相似试验
尚未招募
不适用
An investigator initiated study to study how well does a newly developed spirometer by Cipla Ltd. work as compared to the spirometer already available in the market.CTRI/2019/08/020738Chest Research Foundation
已完成
Unknown
Clinical Study to Compare and Evaluate the Pharmacokinetics and Safety of Vildagliptin SR and Galvus Tab. and Evaluate the Food Effect on the Pharmacokinetics of Vildagliptin SR in Healthy Adult VolunteersKCT0008397Alvogen Korea42
已完成
1 期
A three-dose study of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) in fasting conditions to determine the difference in absorption when dosed differently in healthy male participantsGNE MyopathyMusculoskeletal - Other muscular and skeletal disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12620001127998niversity of South Australia12
已完成
Unknown
A study to examine the comparative exposure of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) when administered orally as a solution and two novel tablet formulations in healthy adult malesGNE MyopathyMusculoskeletal - Other muscular and skeletal disordersHereditary Inclusion Body MyopathyACTRN12623000609651niversity of South Australia6
已完成
不适用
Comparison between the SpirofyTM Spirometer newly developed by Cipla Ltd. with an existing Spirometer (Vitalograph Alpha Touch Spirometer) in healthy, asthmatic and COPD SubjectsCTRI/2021/09/036492Cipla Limited90